The Impact of State Medicaid Eligibility and Benefits Policy on Neonatal Abstinence Syndrome Hospitalizations
- PMID: 38463202
- PMCID: PMC10923531
- DOI: 10.1111/coep.12623
The Impact of State Medicaid Eligibility and Benefits Policy on Neonatal Abstinence Syndrome Hospitalizations
Abstract
Rates of neonatal abstinence syndrome (NAS) resulting from opioid misuse are rising. However, policies to treat opioid misuse during pregnancy are unclear. We apply a difference-in-differences design to national pediatric discharge records to examine the effects of state Medicaid policies on NAS. Among states in which Medicaid covered two clinically-recommended medications for treating opioid misuse (buprenorphine, methadone), the Affordable Care Act's Medicaid expansion reduced Medicaid-covered NAS hospitalizations. Medicaid expansion did not affect NAS hospitalizations in other expansion states. These findings imply a nuanced relationship between Medicaid policy and NAS that should be considered in addressing opioid misuse among pregnant women.
Keywords: Medicaid; Neonatal abstinence syndrome; Opioids.
Conflict of interest statement
Conflict of Interest Statement: The authors have no known conflict of interest regarding the subject of this paper.
Figures
References
-
- American Society of Addiction Medicine. (2020). The ASAM National Practice Guideline for the Use of Medication in the Treatment of Addiction Involving Opioid Use: 2020 Focused Update. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplem... - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources